382. Efruxifermin in Compensated Liver Cirrhosis Caused by MASH.
作者: Mazen Noureddin.;Mary E Rinella.;Naga P Chalasani.;Guy W Neff.;K Jean Lucas.;Manuel E Rodriguez.;Madhavi Rudraraju.;Rashmee Patil.;Cynthia Behling.;Mark Burch.;Doreen C Chan.;Erik J Tillman.;Arian Zari.;Brittany de Temple.;Reshma Shringarpure.;Meena Jain.;Timothy Rolph.;Andrew Cheng.;Kitty Yale.
来源: N Engl J Med. 2025年392卷24期2413-2424页
In phase 2 trials involving patients with stage 2 or 3 fibrosis caused by metabolic dysfunction-associated steatohepatitis (MASH), efruxifermin, a bivalent fibroblast growth factor 21 (FGF21) analogue, reduced fibrosis and resolved MASH. Data are needed on the efficacy and safety of efruxifermin in patients with compensated cirrhosis (stage 4 fibrosis) caused by MASH.
383. Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.
作者: Stephen J Nicholls.;Adam J Nelson.;Marc Ditmarsch.;John J P Kastelein.;Christie M Ballantyne.;Kausik K Ray.;Ann Marie Navar.;Steven E Nissen.;Mariko Harada-Shiba.;Danielle L Curcio.;Annie Neild.;Douglas Kling.;Andrew Hsieh.;Julie Butters.;Brian A Ference.;Ulrich Laufs.;Maciej Banach.;Roxana Mehran.;Alberico L Catapano.;Yong Huo.;Michael Szarek.;Violeta Balinskaite.;Michael H Davidson.; .
来源: N Engl J Med. 2025年393卷1期51-61页
Obicetrapib is a highly selective cholesteryl ester transfer protein inhibitor that reduces low-density lipoprotein (LDL) cholesterol levels. The efficacy and safety of obicetrapib have not been fully characterized among patients at high risk for cardiovascular events.
396. Pegivirus-Associated Encephalomyelitis in Immunosuppressed Patients.
作者: Franziska Scheibe.;Julia Melchert.;Helena Radbruch.;Eberhard Siebert.;Till D Best.;Siegfried Kohler.;Mira Fitzek.;Alexander Kowski.;Volker Siffrin.;Jenny Meinhardt.;Raphael Raspe.;Viktor Horst.;Bianca Zukunft.;Klemens Budde.;Frank K H van Landeghem.;Christopher Power.;Kai-Uwe Eckardt.;Matthias Endres.;Christian Drosten.;Victor M Corman.;Klemens Ruprecht.
来源: N Engl J Med. 2025年392卷18期1864-1866页 |